Page 2 - Patrick Hsu News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The biotech industry is experiencing a rush of AI-powered tools for many aspects of the complex drug discovery process. But one that has flown under the radar,

Atomic AI combines artificial intelligence analysis with wet lab experiments to discover small molecules capable of drugging RNA. The startup, based on technology initially developed at Stanford, is backed by a $35 million Series A round of financing.

With $35M in new funding, Atomic AI aims to do for RNA what AlphaFold did for proteins, and find entirely new treatments in the process.

AI-based drug discovery platform Atomic AI, senior lifestyle company Mighty Health, Lithuania-based Oxipit and cybersecurity firm MedCrypt also closed funding rounds.

New research is "a step forward in understanding viral infection pathways and paves the way for research toward better treatments in the future."

Researchers at UC Berkeley’s Hsu Lab identified human lung proteins that can either promote or restrict infection from SARS-CoV-2.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Check out news from Equiva, Canvas Medical, Particle Health, Fold Health, and Nucleus Genomics.

Nucleus Genomics, cofounded by Caio Hachem, is a direct-to-consumer genetic testing platform that allows users to take control of their genetic data inexpensively.